Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Lymphocytic Interstitial Pneumonia

  • Author: Jussi J Saukkonen, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
 
Updated: Dec 31, 2015
 

Overview

Lymphocytic interstitial pneumonia (LIP) is a syndrome of fever, cough, and dyspnea, with bibasilar pulmonary infiltrates consisting of dense interstitial accumulations of lymphocytes and plasma cells.

LIP may be associated with autoimmune and lymphoproliferative disorders, including rheumatoid arthritis, Hashimoto thyroiditis, myasthenia gravis, pernicious anemia, autoerythrocyte sensitization syndrome, chronic active hepatitis, common variable immunodeficiency, Sjögren syndrome,[1] allogeneic bone marrow transplantation, lupus, and lymphoma. Pseudolymphoma represents a localized masslike variant of LIP. Dysproteinemia has been reported in association with LIP.[2, 3]

LIP is also associated with infection via human immunodeficiency virus (HIV) type 1,[4, 5, 6] Epstein-Barr virus, and human T-cell leukemia virus (HTLV) type 1.

Laboratory test results are nonspecific for LIP. The most essential items in the workup are the chest radiograph, measurement of gas exchange, and histology.

Asymptomatic and physiologically unaffected patients may not require treatment. Symptomatic patients may require supportive care and immunosuppressives, chiefly corticosteroids. Occasionally, cytotoxic therapy has been used. Oxygen supplementation may be considered on the basis of blood gas and/or exercise oximetry findings.

For other discussions on pneumonia, see the following:

Next

Pathophysiology and Etiology

HIV-related lymphocytic interstitial pneumonia (LIP) may be part of a continuum of lymphocytic infiltrative disorders, such as pulmonary lymphoid hyperplasia in children and radiographically clear lymphocytic alveolitis in adults. Patients positive for HLA-DR5 and HLA-DR6 alleles are predisposed to developing a diffuse visceral lymphocytosis syndrome with LIP. LIP has been reported to occur as part of immune reconstitution syndrome.[7]

LIP may result from an in situ lymphoproliferative response to chronically presented viral antigens or cytokines and/or recruitment of circulating lymphocytes. Mutations of the B-cell CLL/lymphoma 6 (BCL-6 or zinc finger protein 51) gene have been associated with LIP and mucosa-associated lymphoid tissue (MALT) lymphoma.[8, 9] Viruses (alone or in combination) may be responsible.[10, 11, 12] Potential candidates include Epstein-Barr virus (EBV), human T-lymphotropic virus 1 (HTLV-1), and HIV-1.

Epstein-Barr virus

DNA from EBV is detected in pediatric LIP lung biopsy specimens when accompanied by evidence of primary or reactivated EBV infection at the time of biopsy. Elevated titers of antibodies directed against EBV have been reported in adult patients with LIP.

HTLV-1

HTLV-1 is associated with a spectrum of pulmonary lymphoproliferative syndromes, including LIP. Serologic and molecular studies have correlated HTLV-1 infection with LIP.

The viral transactivating protein p40Tax activates the genes for interleukin-2 (IL-2) and its receptor’s high-affinity alpha chain. Lymphocyte proliferation driven by IL-2 may cause lymphoproliferative pulmonary lesions related to HTLV-1.

HIV-1

The nef gene product induces an LIP-like syndrome in a transgenic mouse model.

Expression of interleukin-18 (IL-18) and IFN-gamma-inducible chemokines IP-10 and Mig is increased in LIP tissues compared with controls.[13] The beta-chemokines RANTES, MIP1-alpha and MIP1-beta, chemotactic for T cells, are increased in pediatric LIP lesions compared with controls.[13]

Infiltrating B cells are polyclonal. Infiltrating T cells in HIV-related LIP are more commonly oligoclonal expansions than in HIV-negative LIP.[14]

BCL-6 mutations in HIV-associated LIP do not show features of immunoglobulin variable heavy chain (IgV[H]) hypermutations, while HIV-negative LIP BCL-6 mutations do. The immune dysregulation of HIV-associated LIP appears to be a different type than in HIV-negative LIP.

Previous
Next

Epidemiology

Lymphocytic interstitial pneumonia (LIP) is an uncommon disease. In the United States, however, it is found in 22-75% of pediatric patients with HIV who have pulmonary disease. In contrast, among adult patients with HIV, LIP accounts for only 3% of HIV-related pulmonary pathology. Small series have been reported in Europe, southwestern Japan, Africa, and the Caribbean basin.

Most cases of LIP not associated with HIV occur in the fourth and seventh decades of life, at an average age of 56 years. LIP is common only in children with HIV. In children with HIV infection, lymphocytic interstitial pneumonia has been designated an AIDS-defining illness by the US Centers for Disease Control and Prevention.

LIP is more common in women when not associated with HIV infection. HIV-associated sicca syndrome occurs most often in males.[15]

LIP has been found in every race and HIV risk group. Whether racial or geographic predispositions are crucial remains unclear. Many reports describe HIV and HTLV-1–associated LIP among individuals of African ancestry.[16] LIP appears to cluster in southwestern Japan, where HTLV-1 is endemic.

Previous
Next

Prognosis

The clinical course of LIP is variable. The duration is 1 month to 11 years. It often is stable for months without treatment, and sometimes it improves spontaneously. Symptoms often are recurrent and occasionally may lead to end-stage fibrosis or bronchiectasis.

Mortality and morbidity data are inexact because of the lack of reported follow-up, the anecdotal nature of reports, and the rarity of the disease.

In the population who does not have HIV infection, half the patients improve with treatment but relapse is common. End-stage fibrosis may follow despite treatment. In the past, high mortality was reported in older patients.

Patients with HIV-associated LIP display slower decline in CD4+ T-cell counts and longer survival than individuals who have HIV infection but do not have LIP.[17]

Patients with HIV infection but not LIP generally respond to treatment.

Previous
Next

Patient Education

Instructions to patients should include relating all potential toxicities of corticosteroids, including aseptic necrosis of the femoral head, infections, weight gain, hyperglycemia, and other adverse effects. Patients should be instructed to seek medical attention for increased dyspnea or change in sputum.

Previous
Next

Clinical Presentation

Patient history

Symptoms are gradually progressive, often accompanied by constitutional symptoms such as dyspnea and chronic cough. Pleuritic chest pain and hemoptysis are infrequent. Sicca syndrome symptoms may include xerophthalmia and xerostomia.[15]

Physical examination

Manifestations of associated diseases may be present. Physical findings vary in children and adults.

Physical examination findings in children may include the following:

  • Generalized lymphadenopathy
  • Hepatosplenomegaly
  • Parotid enlargement
  • Clubbing
  • Wheezing (occasional)

Physical examination findings in adults may include the following:

  • Generalized lymphadenopathy
  • Rales
  • Hepatosplenomegaly and parotid enlargement: present in approximately one third of adult patients

Complications

Bronchiectasis has been associated with lymphocytic interstitial pneumonia (LIP). Whether this is due to LIP or the frequent bacterial infections these patients experience remains unclear. Bronchitis and pneumonia commonly occur in these patients, with or without bronchiectasis or cystic changes.

Pulmonary fibrosis may be a long-term complication. Generally, it is indolent. Respiratory failure has been reported, especially in the pediatric population.

Malignant transformation to lymphoma or association with lymphoid malignancy has been reported.

Previous
Next

Differential Diagnosis

The differential diagnosis of LIP includes the following:

Other problems to be considered include the following[18, 19, 20] :

  • Angioimmunoblastic lymphadenopathy
  • Benign lymphocytic angiitis
  • Granulomatosis
  • Nonspecific interstitial pneumonitis
  • Plasma cell interstitial pneumonitis
  • Interstitial lung disease
Previous
Next

Laboratory Studies

Laboratory test results are nonspecific for lymphocytic interstitial pneumonia (LIP). Serum protein electrophoresis commonly shows polyclonal hypergammaglobulinemia. In pediatric patients with LIP and HIV, lactate dehydrogenase (LDH) levels may be elevated to 300-500 IU/L, approximately half the levels seen in Pneumocystis carinii pneumonia. This measurement is not helpful in adults. Serologic testing for HIV-1, HTLV-1, EBV, and rheumatoid factor should be carried out.

Previous
Next

Imaging Studies

Chest radiography

Bibasilar interstitial or micronodular infiltrates with coalescence into an alveolar pattern are present (see the image below).

Chest radiograph of lymphocytic interstitial pneum Chest radiograph of lymphocytic interstitial pneumonia in an adult who is HIV positive and has exertional dyspnea, demonstrating characteristic fine bibasilar interstitial markings

In adults, honeycombing is present in up to one third of cases. Hilar adenopathy and pleural effusion are uncommon. Similar infiltrates are seen in children, often with mediastinal widening and hilar enlargement denoting pulmonary lymphoid hyperplasia.

Computed tomography

Computed tomography (CT) scanning reveals the extent of the disease. It may demonstrate bronchiectasis. It also demonstrates the degree of fibrosis.

Findings may be used to follow disease progression. Long-term follow-up may show the development of fibrosis, bronchiectasis, micronodules, bullae, and/or cystic changes.[21, 22]

Previous
Next

Other Tests

Arterial blood gas measurement

Arterial blood gas measurement may be helpful in assessing the severity of illness, but the findings are nonspecific.

Partial pressure of oxygen (PO2) measurement is normal. Profound hypoxemia and/or an increased alveolar to arterial (A-a) oxygen gradient is present. Pulse oximetry is used for screening, but it may not detect an A-a gradient. It should be checked at rest and following exercise. See the A-a Gradient calculator.

Pulmonary function testing

Pulmonary function testing usually demonstrates restriction with a reduced or normal diffusion capacity. Obstructive airway disease has been reported occasionally.

Previous
Next

Biopsy and Histologic Findings

Generally, bronchoscopy with transbronchial biopsy is diagnostic if multiple biopsies are obtained from several affected subsegments. Exact sensitivity and specificity of transbronchial biopsy is not reported.

Open lung biopsy is the criterion standard. It may be required in the face of nonspecific or equivocal findings, as with extensive fibrosis.

Histology shows alveolar septal and intra-alveolar infiltration by small, mature, noncleaved polyclonal lymphocytes and plasma cells. Lymphoid follicles or micronodules also may be present. No intrapulmonary lymphadenopathy, vasculitis, or necrosis is observed. Extensive areas of interstitial fibrosis may be present. Noncaseating granulomata have been reported.

Previous
Next

Treatment and Management

Asymptomatic and physiologically unaffected patients may not require treatment. Symptomatic patients may require supportive care and immunosuppressives, chiefly corticosteroids. Occasionally, cytotoxic therapy has been used. No controlled treatment trials have been reported.[23]

In pediatric patients with HIV, empiric treatment for lymphocytic interstitial pneumonia (LIP) often is initiated based on the findings of subacute dyspnea, mild hypoxemia, and clubbing.

Medications should be used in patients who are symptomatic or physiologically compromised.

Corticosteroids

Corticosteroids are used if the patient is symptomatic and/or has physiologic compromise due to LIP. Risks of infection, osteoporosis, hyperglycemia, weight gain, dermatologic changes, and other potential toxicities should be weighed against any potential benefit.

One report describes dramatic improvement in LIP associated with common variable immunodeficiency treated with intravenous immunoglobulin without steroids.[24]

Alkylating agents

Alkylating agents are used when disease is refractory to corticosteroid therapy. They should be considered only in cases clearly unresponsive to corticosteroids used in high dosage. These agents should only be prescribed by physicians familiar with usage and toxicities. They are generally prescribed for several weeks at a time; disease manifestations and complete blood count should be monitored.

Other agents

Antibiotics are used for associated pulmonary infections.

LIP has been reported to improve with the use of zidovudine alone. Highly active antiretroviral therapy (HAART) may result in improvement or resolution of LIP in some instances.[7]

Bronchodilators may be used for associated wheezing.

Oxygen supplementation

Activity may be limited by exercise-induced oxygen desaturation. Perform exercise oximetry to determine if supplementary oxygen is needed. Consider oxygen supplementation based on blood gas and/or exercise oximetry findings.

Previous
Next

Consultations

Consultation with a pulmonologist or thoracic surgeon may be necessary to obtain transbronchial biopsy or open lung biopsy, respectively.

In cases associated with HIV infection, consultation with a specialist familiar with HIV care is recommended.

Previous
Next

Further Care of Patients

Steps for inpatients

Steps for inpatients include the following:

  • Exclude pulmonary infections.
  • Determine whether oxygenation is adequate. Arrange for ambulatory supplementary oxygen if necessary.
  • If a transbronchial or open lung biopsy has been performed, either exclude postprocedure pneumothorax or demonstrate that it is small and stable by means of expiratory chest radiographs.

Steps for outpatients

Periodically perform pulse oximetry at rest and with exercise. Encourage consistent use of a standardized exercise course, such as a long corridor or several flights of steps.

Obtain periodic chest radiographs and/or chest CT scan, which are used for the following purposes:

  • To assess for improvement on therapy
  • To help detect exacerbation of lymphocytic interstitial pneumonia or other pulmonary pathology, notably infections
  • To assess for residual fibrosis

Make every attempt to determine if remaining respiratory compromise is related to pulmonary fibrosis or some other pulmonary pathology.

Obtain clinical reevaluation, radiography, and/or chest CT scan if the patient continues to require high-dose steroids. A change in sputum may be the only sign of infection.

Modification of medication regimen

After the first month of therapy and if disease activity allows it, gradually taper the prednisone dosage. Use the lowest possible dose to suppress this chronic interstitial pneumonitis. Monitor the patient for signs of infection and other toxicities of corticosteroid or immunosuppressive therapy.

Evaluation for transfer

Adequate gas exchange and a stable airway are required. Appropriate medical records and copies of actual chest radiographs should be transferred.

Previous
 
Contributor Information and Disclosures
Author

Jussi J Saukkonen, MD Associate Professor, Department of Internal Medicine, Division of Pulmonary/Critical Care Medicine, Boston University School of Medicine, Boston Medical Center

Jussi J Saukkonen, MD is a member of the following medical societies: American Thoracic Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Daniel R Ouellette, MD, FCCP Associate Professor of Medicine, Wayne State University School of Medicine; Chair of the Clinical Competency Committee, Pulmonary and Critical Care Fellowship Program, Senior Staff and Attending Physician, Division of Pulmonary and Critical Care Medicine, Henry Ford Health System; Chair, Guideline Oversight Committee, American College of Chest Physicians

Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, Society of Critical Care Medicine, American Thoracic Society

Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women's Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

Stephen P Peters, MD, PhD, FACP, FAAAAI, FCCP, FCPP Thomas H Davis Chair in Pulmonary Medicine, Chief, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Professor of Internal Medicine, Pediatrics, and Translational Science, Associate Director, Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine; Executive Director of the Respiratory Service Line, Wake Forest Baptist Medical Center

Stephen P Peters, MD, PhD, FACP, FAAAAI, FCCP, FCPP is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society, Sigma Xi

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Integrity CE, Merck<br/>Received income in an amount equal to or greater than $250 from: – Array Biopharma, AstraZeneca, Aerocrine, Airsonett AB, Boehringer-Ingelheim, Experts in Asthma, Gilead, GlaxoSmithKline, Merck, Novartis, Ono Pharmaceuticals, Pfizer, PPD Development, Quintiles, Sunovion, Saatchi & Saatichi, Targacept, TEVA, Theron.

References
  1. Tokuyasu H, Watanabe E, Okazaki R, Kawasaki Y, Kikuchi R, Isowa N, et al. Sjögren's syndrome with multiple bullae caused by lymphocytic interstitial pneumonia. Lung. 2007 May-Jun. 185(3):187-8. [Medline].

  2. Greenberg SD, Haley MD, Jenkins DE, Fischer SP. Lymphoplasmacytic pneumonia with accompanying dysproteinemia. Arch Pathol. 1973 Aug. 96(2):73-80. [Medline].

  3. Liebow AA, Carrington CB. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin North Am. 1973 May. 57(3):809-43. [Medline].

  4. Grieco MH, Chinoy-Acharya P. Lymphocytic interstitial pneumonia associated with the acquired immune deficiency syndrome. Am Rev Respir Dis. 1985 Jun. 131(6):952-5. [Medline].

  5. Lin RY, Gruber PJ, Saunders R, Perla EN. Lymphocytic interstitial pneumonitis in adult HIV infection. N Y State J Med. 1988 May. 88(5):273-6. [Medline].

  6. Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr Pulmonol. 2008 Jan. 43(1):1-10. [Medline].

  7. Ingiliz P, Appenrodt B, Gruenhage F, Vogel M, Tschampa H, Tasci S, et al. Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation. HIV Med. 2006 Sep. 7(6):411-4. [Medline].

  8. Kurosu K, Weiden MD, Takiguchi Y, Rom WN, Yumoto N, Jaishree J, et al. BCL-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia. J Immunol. 2004 Jun 1. 172(11):7116-22. [Medline].

  9. Wu W, Zhou J, Di LG, Chen H. From lymphocytic interstitial pneumonia to MALT lymphoma of lung: a case report with a 5-year diagnostic dilemma. Int J Clin Exp Pathol. 2015. 8 (8):9698-702. [Medline].

  10. Morris JC, Rosen MJ, Marchevsky A, Teirstein AS. Lymphocytic interstitial pneumonia in patients at risk for the acquired immune deficiency syndrome. Chest. 1987 Jan. 91(1):63-7. [Medline].

  11. Semenzato G, Agostini C. Human retroviruses and lung involvement. Am Rev Respir Dis. 1989 Jun. 139(6):1317-22. [Medline].

  12. Setoguchi Y, Takahashi S, Nukiwa T, Kira S. Detection of human T-cell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia. Am Rev Respir Dis. 1991 Dec. 144(6):1361-5. [Medline].

  13. Teruya-Feldstein J, Kingma DW, Weiss A, Sorbara L, Burd PR, Raffeld M, et al. Chemokine gene expression and clonal analysis of B cells in tissues involved by lymphoid interstitial pneumonitis from HIV-infected pediatric patients. Mod Pathol. 2001 Oct. 14(10):929-36. [Medline].

  14. Kurosu K, Yumoto N, Rom WN, Takiguchi Y, Jaishree J, Nakata K, et al. Oligoclonal T cell expansions in pulmonary lymphoproliferative disorders: demonstration of the frequent occurrence of oligoclonal T cells in human immunodeficiency virus-related lymphoid interstitial pneumonia. Am J Respir Crit Care Med. 2002 Jan 15. 165(2):254-9. [Medline].

  15. Couderc LJ, D'Agay MF, Danon F, Harzic M, Brocheriou C, Clauvel JP. Sicca complex and infection with human immunodeficiency virus. Arch Intern Med. 1987 May. 147(5):898-901. [Medline].

  16. Rio B, Louvet C, Gessain A, Dormont D, Gisselbrecht C, Martoia R, et al. [Adult T-cell leukemia and non-malignant adenopathies associated with HTLV I virus. Apropos of 17 patients born in the Caribbean region and Africa]. Presse Med. 1990 Apr 21. 19(16):746-51. [Medline].

  17. Qin L, Wang W, Liu H, Xiao Y, Qin M, Zheng W, et al. Prognosis of nonspecific interstitial pneumonia correlates with perivascular CD4+ T lymphocyte infiltration of the lung. BMC Pulm Med. 2015 Oct 24. 15:127. [Medline].

  18. Strimlan CV, Rosenow EC 3rd, Weiland LH, Brown LR. Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med. 1978 May. 88(5):616-21. [Medline].

  19. Travis WD, Fox CH, Devaney KO, Weiss LM, O'Leary TJ, Ognibene FP, et al. Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus nonspecific interstitial pneumonitis. Hum Pathol. 1992 May. 23(5):529-41. [Medline].

  20. White DA, Matthay RA. Noninfectious pulmonary complications of infection with the human immunodeficiency virus. Am Rev Respir Dis. 1989 Dec. 140(6):1763-87. [Medline].

  21. Becciolini V, Gudinchet F, Cheseaux JJ, Schnyder P. Lymphocytic interstitial pneumonia in children with AIDS: high-resolution CT findings. Eur Radiol. 2001. 11(6):1015-20. [Medline].

  22. Johkoh T, Ichikado K, Akira M, Honda O, Tomiyama N, Mihara N, et al. Lymphocytic interstitial pneumonia: follow-up CT findings in 14 patients. J Thorac Imaging. 2000 Jul. 15(3):162-7. [Medline].

  23. Saito M, Hatakeyama S, Wakabayashi Y, Yanagimoto S, Takemura T, Yotsuyanagi H. A pathologically proven case of adult-onset HIV-related lymphocytic interstitial pneumonia with acute exacerbation treated with steroid and antiretroviral therapy. J Infect Chemother. 2015 Aug 19. [Medline].

  24. Arish N, Eldor R, Fellig Y, Bogot N, Laxer U, Izhar U, et al. Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins. Thorax. 2006 Dec. 61(12):1096-7. [Medline]. [Full Text].

  25. Montes M, Tomasi TB Jr, Noehren TH, Culver GJ. Lymphoid interstitial pneumonia with monoclonal gammopathy. Am Rev Respir Dis. 1968 Aug. 98(2):277-80. [Medline].

 
Previous
Next
 
Chest radiograph of lymphocytic interstitial pneumonia in an adult who is HIV positive and has exertional dyspnea, demonstrating characteristic fine bibasilar interstitial markings
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.